Patients who were with HER2-positive and triple-negative BrCa tended to express higher FMNL1 and FMNL2 mRNA levels (Figures 3(a), 3(b), 3(d), and 3(e)) while expressed lower FMNL3 mRNA (Figures 3(c) and 3(f)). This evidence concerns the gene ERBB2 and invasive breast carcinoma.